BioSpace News Archive

Ring Therapeutics announced new preclinical data demonstrating successful transduction and redosability of its Anellovector within non-human primates, as well as expanded payload capacity for the vector beyond the natural genome size of anelloviruses.

X4 Pharmaceuticals reported financial results for the first quarter ended March 31, 2024 and highlighted key recent and upcoming expected milestones.

IDEAYA Biosciences, Inc. provided a business update, and announced financial results for the first quarter ended March 31, 2024.

Aurinia Pharmaceuticals Inc. announced that it will attend the 2024 RBC Capital Markets Global Healthcare Conference in New York from May 14-15, 2024.

Neurogene Inc. announced initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome, which showed that NGN-401 was generally well-tolerated by all three patients dosed, with follow-up of approximately nine, six and three months post-dosing.

Design Therapeutics, Inc. announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York.

Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that the Company will participate in the following upcoming investor conferences in May: 2024 RBCCM Global Healthcare Conference : fireside chat on Tuesday, May 14, 2024 at 11:30 a.m. ET.

SOPHiA GENETICS, a cloud-native software company and leader in data-driven medicine, reported financial results for the first quarter ended March 31, 2024.

Waters Corporation announced its financial results for the first quarter of 2024.

InspireMD, Inc., developer of the CGuard™ Embolic Prevention Stent System device for the treatment of Carotid Artery Disease and stroke prevention, announced it will report first quarter 2024 financial results on Tuesday, May 14th, before the financial markets open.